By prioritizing staff education, starting small with practical applications, and establishing clear guidelines, local health departments can lay the foundation for sustainable AI adoption. This approach ultimately enhances efficiency, improves health outcomes, and ensures cost-effective care for the communities they serve. The post Bridging the AI Gap in Local Health: Practical Steps for Adoption appeared…
Inozyme Pharma’s main asset is in pivotal testing in children who have a rare enzyme deficiency that affects bones and blood vessels. BioMarin Pharmaceutical, already well established in enzyme replacement, said it will use its experience and infrastructure to grow the market for this product, potentially for several indications. The post BioMarin’s $270M Inozyme Acquisition…
Homeless shelters and FQHCs will begin using a common platform to improve care coordination
In this episode, we’re joined by Margaret Malone, principal of Flare Capital Partners. She discusses the investment trends she’s following in the women’s health space and advice she has for startups. The post MedCity FemFwd: Investment Trends In Women’s Health appeared first on MedCity News.
More than two in five (42%) or 57.4 million adults under 65 with private insurance could be eligible under clinical criteria for GLP-1 drugs used to treat people with type 2 diabetes, obesity, or excess weight and weight-related health issues, according to a new KFF analysis. Though only about 3% of adults with employer coverage…More
You can provide the best care possible inside the four walls of your hospital, but if your patients can’t afford their prescriptions after you discharge them, the system isn’t working. The post The Cost of Medication Non-Adherence — How Hospitals Can Close the Gap through Better Communication appeared first on MedCity News.
More than a decade ago, Medtronic announced that a pivotal trial testing its renal denervation system had failed. Though it got approved later, reimbursement has been elusive. All that might change this year. The post Is Medtronic On the Cusp of Rewriting the Story of Renal Denervation? appeared first on MedCity News.
This Policy Watch provides an update on the status of PEPFAR reauthorization, which expired on March 25, 2025, allowing certain provisions to lapse.
HAMILTON, Mont. — Scientists are often careful to take off their work badges when they leave the campus of one of the nation’s top research facilities, here in southwestern Montana’s Bitterroot Valley. It’s a reflection of the long-standing tension caused by Rocky Mountain Laboratories’ improbable location in this conservative, blue-collar town of 5,000 that was…
From the CMS document “Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2027“: On January 17, 2025, CMS announced the selection of the below list of 15 drugs covered under Medicare Part D for the second cycle of negotiations (initial price applicability year 2027), based on total gross covered prescription drug…